MATTHEW HODERLEIN: Open Payments
NPI 1811663875 · PENFIELD, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,337 in 174 payments from 13 companies in 2025. Trend: 2023 $165 · 2024 $836 · 2025 $4,337
Food & beverage: $4,337
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $717 |
| Vanda Pharmaceuticals Inc. | 23 | $666 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $513 |
| Axsome Therapeutics, Inc. | 17 | $457 |
| Otsuka America Pharmaceutical, Inc. | 17 | $359 |
| Neurocrine BioSciences, Inc. | 14 | $358 |
| Janssen Pharmaceuticals, Inc | 12 | $344 |
| Lundbeck LLC | 10 | $273 |
| Teva Pharmaceuticals USA, Inc. | 5 | $189 |
| E.R. Squibb & Sons, L.L.C. | 3 | $154 |
Products named: VRAYLAR, REXULTI, CAPLYTA, Auvelity, INGREZZA, FANAPT, SPRAVATO, HETLIOZ.
Industry payments across NY — which companies pay providers there.
